Advertisement

Drugs in R & D

, Volume 9, Issue 3, pp 185–190 | Cite as

Alfimeprase

Adis R&D Profile

Keywords

Acute Ischaemic Stroke Alteplase Central Venous Access Device Thrombolytic Activity Target Product Profile 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Nuvelo Inc. Nuvelo Resumes Development of Alfimeprase in Multiple Blood-Clot Related Indications. Media Release: 26 Jun 2007. Available from URL: http://www.nuvelo.com Google Scholar
  2. 2.
    Nuvelo Inc. Nuvelo to Gain Worldwide Rights to Alfimeprase Through Amgen Licensing Agreement. Media Release: 1 Nov 2004. Available from URL: http://www.nuvelo.com Google Scholar
  3. 3.
    Nuvelo Inc. Nuvelo Reduces Expenses and Realigns Organization To Focus on Programs Expected To Yield Nearest-Term Proof-of-Concept Data. Media Release: 2 Aug 2007. Available from URL: http://www.nuvelo.com Google Scholar
  4. 4.
    Nuvelo Inc. Nuvelo and Bayer HealthCare Enter Comprehensive Collaboration Agreement to Maximize Global Development and Commercialization of Alfimeprase. Media Release: 5 Jan 2006. Available from URL: http://www.nuvelo.com Google Scholar
  5. 5.
    Nuvelo Inc. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development. Media Release: 17 Mar 2008. Available from URL: http://www.nuvelo.com Google Scholar
  6. 6.
    Nuvelo Inc, Bayer HealthCare. Nuvelo and Bayer Healthcare Announce Phase 3 Trials of Alfimeprase in Patients With Acute Peripheral Arterial Occlusion and Catheter Occlusion Did Not Meet Primary Endpoints. Media Release: 12 Dec 2006. Available from URL: http://www.nuvelo.com. Summary in 2 parts (Part A)Google Scholar
  7. 7.
    Nuvelo Inc. Nuvelo Announces Results from Phase 3 NAPA Program in Acute Peripheral Arterial Occlusion. Media Release: 24 Jan 2008. Available from URL: http://www.nuvelo.com. Summary in 2 parts (Part A)Google Scholar
  8. 8.
    Nuvelo Inc. Nuvelo Announces Completion of Patient Enrollment in NAPA-2, First Phase 3 Trial of Alfimeprase in Acute Peripheral Arterial Occlusion. Media Release: 5 Sep 2006. Available from URL: http://www.nuvelo.com Google Scholar
  9. 9.
    Nuvelo Inc. Nuvelo Reports First Quarter 2006 Financial Results and Accomplishments. Media Release: 5 May 2006. Available from URL: http://www.nuvelo.com Google Scholar
  10. 10.
    Nuvelo Inc. Nuvelo and Bayer Healthcare Begin NAPA-3, Second Pivotal Phase 3 Trial of Alfimeprase for Acute Peripheral Arterial Occlusion. Media Release: 10 Apr 2006. Available from URL: http://www.nuvelo.com Google Scholar
  11. 11.
    Novel Arterial Perfusion with Alfimeprase (NAPA) Investigators. Alfimeprase, a novel direct-acting fibrinolytic agent in acute peripheral arterial occlusion: report of a phase 2, multi-center, open-label, dose-defining study. Circulation 114 (Suppl.): 648 (plus poster) abstr. 2777, No. 18, 31 Oct 2006CrossRefGoogle Scholar
  12. 12.
    Nuvelo Inc. Nuvelo Announces the Completion of Its Phase 2 Alfimeprase Trial in Acute Peripheral Arterial Occlusion. Media Release: 28 Jun 2004. Available from URL: http://www.nuvelo.com Google Scholar
  13. 13.
    Nuvelo Inc. Nuvelo Phase 2 Clinical Trial Results Show Potential of Alfimeprase to Treat Acute Peripheral Arterial Occlusion, Also Known as ‘Leg Attack’. Media Release: 30 Sep 2004. Available from URL: http://www.nuvelo.com Google Scholar
  14. 14.
    Nuvelo Inc. Nuvelo Announces Successful Results in Phase I Clinical Trial. Media Release: 27 Mar 2003. Available from URL: http://www.nuvelo.com Google Scholar
  15. 15.
    Nuvelo Inc. Nuvelo Announces Completion of Patient Enrollment in SONOMA-2, First Phase 3 Trial of Alfimeprase in Central Venous Catheter Occlusion. Media Release: 5 Sep 2006. Available from URL: http://www.nuvelo.com Google Scholar
  16. 16.
    Nuvelo Inc, Bayer HealthCare. Nuvelo and Bayer HealthCare Begin SONOMA-3, Second Phase 3 Trial of Alfimeprase in Patients With Central Venous Catheter Occlusion. Media Release: 27 Feb 2006. Available from URL: http://www.nuvelo.com Google Scholar
  17. 17.
    Nuvelo Inc. Nuvelo Reports Third Quarter 2005 Financial Results and Accomplishments. Media Release: 1 Nov 2005. Available from URL: http://www.nuvelo.com Google Scholar
  18. 18.
    Nuvelo Inc. Nuvelo Begins Phase 3 Program Evaluating Alfimeprase in Patients With Central Venous Catheter Occlusion. Media Release: 6 Sep 2005. Available from URL: http://www.nuvelo.com Google Scholar
  19. 19.
    Nuvelo Inc. Nuvelo Announces Design of Phase 3 Alfimeprase Program in Patients With Central Venous Catheter Occlusion. Media Release: 26 May 2005. Available from URL: http://www.nuvelo.com. Summary in 2 parts (Part A)Google Scholar
  20. 20.
    Nuvelo Inc. Nuvelo Provides 2006 Clinical Guidance at JPMorgan Conference. Media Release: 9 Jan 2006. Available from URL: http://www.nuvelo.com Google Scholar
  21. 21.
    Nuvelo Inc. Nuvelo Announces Publication of Phase 2 Alfimeprase Study Results in Central Venous Catheter Occlusion. Media Release: 6 Jul 2006. Available from URL: http://www.nuvelo.com Google Scholar
  22. 22.
    Nuvelo Inc. Nuvelo Reports Successful Completion of Interim Analysis in Phase 2 Trial With Alfimeprase in Catheter Occlusion. Media Release: 8 Jun 2004. Available from URL: http://www.nuvelo.com Google Scholar
  23. 23.
    Nuvelo Inc. Nuvelo Announces Strategy to Accelerate Catheter Occlusion Program. Media Release: 12 Jul 2004. Available from URL: http://www.nuvelo.com Google Scholar
  24. 24.
    Nuvelo Inc. Nuvelo Initiates Phase II Clinical Trial in Catheter Occlusion. Media Release: 5 Jun 2003. Available from URL: http://www.nuvelo.com Google Scholar
  25. 25.
    Nuvelo Inc. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke. Media Release: 12 Dec 2007. Available from URL: http://www.nuvelo.com Google Scholar
  26. 26.
    Moll S, Gabrail N, Buchanan J, et al. Safety and efficacy of alfimeprase in subjects with occluded central venous access devices: the SONOMA-2 study. Blood 110: 552–553 (plus poster) abstr. 1866, No. 11, Part 1, Nov 2007Google Scholar
  27. 27.
    Nuvelo Inc. Nuvelo Announces Publication of Alfimeprase Phase 1 Clinical Trial Results. Media Release: 8 Aug 2005. Available from URL: http://www.nuvelo.com Google Scholar

Copyright information

© Adis Data Information BV 2008

Personalised recommendations